Literature DB >> 20005029

Prevention of diabetic kidney disease: negative clinical trials with renin-angiotensin system inhibitors.

Robert G Nelson1, Katherine R Tuttle.   

Abstract

Entities:  

Year:  2009        PMID： 20005029      PMCID： PMC3480512          DOI： 10.1053/j.ajkd.2009.10.001

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  20 in total

1.  K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2004-05       Impact factor: 8.860

2.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Authors:  Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

3.  Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group.

Authors: 
Journal:  Lancet       Date:  1997-06-21       Impact factor: 79.321

4.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.

Authors:  Anushka Patel; S MacMahon; J Chalmers; B Neal; M Woodward; L Billot; S Harrap; N Poulter; M Marre; M Cooper; P Glasziou; D E Grobbee; P Hamet; S Heller; L S Liu; G Mancia; C E Mogensen; C Y Pan; A Rodgers; B Williams
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

6.  Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

Authors:  Rudy Bilous; Nish Chaturvedi; Anne Katrin Sjølie; John Fuller; Ronald Klein; Trevor Orchard; Massimo Porta; Hans-Henrik Parving
Journal:  Ann Intern Med       Date:  2009-05-18       Impact factor: 25.391

7.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

8.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

9.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321
View more
  6 in total

1.  Reversibility of structural and functional damage in a model of advanced diabetic nephropathy.

Authors:  Warangkana Pichaiwong; Kelly L Hudkins; Tomasz Wietecha; Tri Q Nguyen; Chiraporn Tachaudomdach; Wei Li; Bardia Askari; Takahisa Kobayashi; Kevin D O'Brien; Jeffrey W Pippin; Stuart J Shankland; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2013-05-02       Impact factor: 10.121

Review 2.  The goal of blood pressure control for prevention of early diabetic microvascular complications.

Authors:  Mark E Williams
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

3.  Retracted Article: Ligustrazine attenuates renal damage by inhibiting endoplasmic reticulum stress in diabetic nephropathy by inactivating MAPK pathways.

Authors:  Hongling Yang; Shukun Wu
Journal:  RSC Adv       Date:  2018-06-13       Impact factor: 4.036

4.  Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes.

Authors:  Masumi Kamiyama; Andrea Zsombok; Hiroyuki Kobori
Journal:  J Pharmacol Sci       Date:  2012-07-31       Impact factor: 3.337

5.  Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.

Authors:  Zeng Si Wang; Fei Xiong; Xiao Hang Xie; Dan Chen; Jian Hua Pan; Li Cheng
Journal:  BMC Nephrol       Date:  2015-03-31       Impact factor: 2.388

6.  Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice.

Authors:  Gaofeng Song; Pengxun Han; Huili Sun; Mumin Shao; Xuewen Yu; Wenjing Wang; Dongtao Wang; Wuyong Yi; Na Ge; Shunmin Li; Tiegang Yi
Journal:  J Int Med Res       Date:  2018-06-13       Impact factor: 1.671
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.